Tech Stumbles, Small Caps Strut, JpmHc2026 Day 3, Silver, Gold, Bitcoin Pop- January 14, 2026 -( $CRML $EPRX $INTC $MTWO $NBTX $RIO $SER $SOAR $VKTX Rise!)

Wall Street ended Wednesday with big tech nursing a hangover, small caps stealing the limelight, and investors once again discovering that the yield curve has a better sense of drama than most streaming services.

Indexes: Big Tech Blinks, Small Caps Smirk

The Nasdaq Composite led the retreat, sliding about 1% as a broad selloff in Nvidia and its semiconductor peers pressured the growth complex. The S&P 500 followed lower, shedding roughly 0.53% as mega-cap tech gave back a sliver of its recent outsized gains

The Dow Jones Industrial Average proved more decorous, dipping only around .09% as its old-economy ballast cushioned the tech weakness. By contrast, the Russell 2000 quietly played hero, up about 0.7% on the day and roughly 6.84% year-to-date as small caps enjoyed a rare moment in the spotlight at big tech’s expense.

Macro: Inflation Cool, Data Calendar Bent, Not Broken

On the inflation front, wholesale prices continued to underwhelm the pessimists, with the Producer Price Index rising less than expected and reinforcing the narrative that pricing pressures are easing rather than reaccelerating. Recent data showed core consumer inflation at 0.2% month-on-month in December and 2.6% year-on-year, a four‑year low that has allowed markets to lean further into the “disinflation plus growth” story.

The government shutdown’s earlier disruption of federal statistics left the economic calendar looking like a shuffled deck, with agencies now phasing in delayed releases on revised timetables and tweaking some report formats to catch up. Tariff‑related data showed U.S. tariff revenues hitting a record $264 billion in 2025 but declining in the last two months of the year after President Trump trimmed some levies; analysts note that pass‑through to consumer prices has so far been notably milder than feared.

Rates, Yield Curve, Fed, and Washington

Treasury yields drifted lower, with the 10‑year note hovering near 4.15–4.18%, leaving the curve still positively sloped but far from relaxed. The 20‑year yield sat around 4.77%, modestly below recent peaks, while curve spreads such as the 10‑year minus 3‑month rate remained in the black, pointing to a “steepening-lite” regime as investors handicap a Fed near the end of its cutting cycle. The 2-yr came in at 3.520%.

The Federal Reserve’s next policy set‑piece arrives at the January 27–28 FOMC meeting, with Chair Powell scheduled for the customary press conference on the 28th and no rate change widely expected. Market commentary has increasingly framed 2026 as a year of transition to a neutral fed funds range near 3.5–3.75%, a level seen as restrictive enough to keep inflation in check but no longer an outright brake on activity. In Washington, the aftershocks of last year’s government shutdown are still visible in the data pipeline, but there is no fresh shutdown drama on today’s docket, and the fiscal conversation has shifted back toward deficits and the optics of using tariffs as a budgetary crutch.finance.yahoo+4​

Trade and Tariffs: Policy by Tweet and Footnote

Tariffs remained a policy wildcard, but not a market‑breaking one. New Treasury figures highlighted that while 2025 tariff revenues hit record levels, monthly inflows slipped in November and December after Trump’s partial rollback, highlighting the limits of tariffs as a fiscal tool. Economists also pointed out that core goods prices have been almost eerily well‑behaved, suggesting that the feared torrent of tariff‑driven consumer inflation has so far amounted to more of a steady drizzle.

The tariff conversation took on a fresh geopolitical edge, with the White House floating threats of 25% tariffs on countries “doing business” with Iran even as markets awaited a potential Supreme Court ruling on the administration’s broad tariff authority—a reminder that the trade rulebook remains a living, heavily annotated document.

Commodities and Crypto: Shiny Things and Digital Gold

In commodities, the precious‑metals crowd enjoyed another day of vindication, as gold futures hovered near record territory at 4,633.90/oz., +.76%, while silver ended at $93.185/oz. upon 7.93%—up nearly 30% year‑to‑date and having almost tripled over the past year—continued to behave less like a hedge and more like a high‑beta macro thesis. Oil prices stayed buoyant after a recent rally, with crude holding above key resistance near the low‑$61s as supply jitters and Middle East tensions kept a firm bid under the barrel complex.

Bitcoin traded up around ~3.29% to there $97.8k range, remaining inside an upward‑sloping bullish channel that technicians describe as still intact despite signs of a short‑term corrective phase; the consensus view remains that any pullback toward support in the low‑$90,000s would likely invite another round of dip buying. In a world where gold, silver, and digital gold are all flirting with new highs, diversification increasingly looks less like prudence and more like fear of missing out in triplicate.

Corporate Tape: AI Darlings, Chips, and Old Economy Stalwarts

The session’s equity narrative was dominated by a rotation away from mega‑cap tech and AI plays, even as Wall Street’s research machinery continued to shower them with superlatives.​

• Eli Lilly (LLY, $,073.29, -.36%): Shares remained underpinned by the company’s status as a weight‑loss and diabetes powerhouse, after a 39% gain in 2025 and a recent milestone as the first healthcare group to cross the $1 trillion market‑cap line, but near‑term trading was choppy as investors weighed lofty valuations against still‑accelerating earnings forecasts.
• Taiwan Semiconductor (TSM, $327.11, -1.24%): TSM traded near record territory but slipped modestly as investors squared positions ahead of Thursday’s earnings; the company recently reported a roughly 20% year‑on‑year jump in fourth‑quarter revenue and won a series of price‑target hikes on expectations of 30% revenue growth in 2026 driven by AI demand.
• Nvidia (NVDA, $183.14, -1.44%) and Micron (MU, $333.35,-1.41%): Nvidia was at the epicenter of the tech pullback, with the stock under pressure after the Trump administration ordered new security protocols before exports of high‑end AI chips to China, contributing to the Nasdaq’s underperformance. Micron moved in sympathy with the broader chip complex as investors reassessed just how far and fast the AI memory cycle can run.
• Apple and Tesla: Apple eased alongside the mega‑cap cohort despite a recent vote of confidence from Bank of America, which reiterated a bullish stance heading into late‑January earnings on the back of strong iPhone and Services trends. Tesla slipped as well to $439.20, weighed by an Underweight call from Wells Fargo that highlighted skepticism about the company’s robotaxi ambitions even as it nudged its price target higher.
• Broadcom (AVGO, $339.89, -4.15%) and Meta ($615.52, -2.47%): Broadcom, another AI infrastructure bellwether, joined the day’s semiconductor retreat despite being re‑endorsed as a top pick by Bernstein, which argued that AI‑driven spending still has ample room to run. Meta traded off recent highs but remained supported by bullish research citing a robust 2026 earnings and capex profile.cnbc+1​
• Nokia (NOK, $6.36, -2.45%) and McDonald’s: Nokia’s shares were relatively subdued, with the stock drifting as investors awaited clearer signs that its restructuring and 5G cycle can translate into sustained top‑line growth. McDonald’s, a defensive staple, traded more resiliently to close at $308.13, -.42%, benefiting from its status as both an inflation hedge for value‑seeking diners and a dependable dividend payer.
• Rio Tinto (RIO, $85.88, +2.74%), Intel: Rio Tinto rode the broader metals and mining optimism sparked by record gold and strong copper prices, as investors leaned into hard‑asset plays. Intel (INTC) lead the AI elite rosing 3.02% closing at $48.72.
• OKLO, Opendoor, Palantir: Nuclear‑energy hopeful Oklo traded as a high‑beta clean‑energy play, swaying with sentiment rather than headlines closing at $95.97, -1.15%. Opendoor (OPEN, $6.64, -1.92%) moved with the housing and rate complex. Palantir (PLTR, $178.40,-.31%) stayed on growth investors’ radar thanks to outsize earnings growth expectations and a recent wave of bullish commentary, including a buy‑rating reset that cast the company as a potential long‑duration “supercycle” winner in data and AI software.

M&A chatter remained active across healthcare and tech, but no landmark new megadeals crossed the tape today; the tone was one of ongoing strategic positioning rather than market‑rocking buyouts. IPO activity on the NYSE and Nasdaq also remained comparatively subdued, with bankers prepping pipelines rather than ringing many bells, as issuers continued to weigh rich valuations against an increasingly discerning buy side.

J.P. Morgan Healthcare, Day 3: Deals, Data, and Diplomacy

The 44th Annual J.P. Morgan Healthcare Conference rolled into its third day in San Francisco, once again doubling as healthcare’s annual strategy summit and speed‑dating festival for capital. AI in healthcare, obesity and cardiometabolic drugs, and a rekindling of biotech M&A remained dominant themes, with big pharma executives threading a careful needle between Washington’s pricing scrutiny and Wall Street’s appetite for pipeline‑in‑a‑box acquisitions.

Presentations from specialty pharma and rare‑disease players, including companies like Recordati (RCDTF, $65.44), Nanbiotix (NBTX, $21.53 +.70%), & Viking Therapeutics (VKTX, $34.34, +11.89%) highlighted how even niche franchises are now framed through the lens of real‑world evidence, pricing durability, and capital discipline—an unmistakable sign that the era of “grow now, justify later” has definitively passed. In the hallways, the conversation mixed GLP‑1s, AI‑enabled clinical development, and the emerging reality that in 2026, healthcare strategy is as much about data architecture as it is about molecules.

Vista Partners Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4609), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, announced (Dec. 10) that it had priced an underwritten public offering (the “offering”) of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. In connection with the offering, Modular Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter’s sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof. Newbridge Securities Corporation is acting as the sole bookrunner for the offering. Assuming no exercise of the over-allotment option, the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts, commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures.

On Nov. 17, Modular announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.

On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $8.20, +1.44%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $2.86), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer.

GeoVax is heading into the 44th Annual J.P. Morgan Healthcare Conference week (“JPM2026”) in San Francisco, CA Jan. 12-15 with the kind of narrative biotech investors typically like to hear: a differentiated platform, large funded trials lining up, and multiple shots on goal in both infectious disease and oncology. The company is leaning into its MVA platform as a potential franchise engine rather than a one‑product science experiment. Specifically, investors can meet David Dodd, Chairman & CEO of GeoVax, during his presentation at the Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA on January 13, 2026, 2:30 pm PST.

GeoVax announced (Dec. 19) that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.

GeoVax announced (Dec. 18) the publication of a peer-reviewed article in Frontiers in Immunology titled: “Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.” The study provides definitive preclinical evidence that GeoVax’s multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivers full cross-variant protection, driven predominantly by robust T-cell responses, even in the absence of neutralizing antibodies. The findings reinforce the design philosophy behind GeoVax’s MVA-based, multi-antigen platform and provide mechanistic insight that is increasingly relevant for immunocompromised individuals, who often fail to respond optimally to the first-generation COVID-19 vaccines.

GeoVax announced (Dec. 17) the successful completion of fill-finish for the initial clinical batch of GEO-MVA, its next-generation Mpox/smallpox vaccine. The product has now entered final release evaluation, the concluding quality-control and compliance process required before shipment for clinical use, positioning the Company for Phase 3 immunobridging trial start-up activities in Q1 2026. Fill-finish – the sterile, cGMP-regulated process of filling, sealing, and packaging vaccine vials – marks the last manufacturing step before a vaccine may enter clinical study supply channels. With fill-finish complete and GEO-MVA now undergoing final release evaluation, GeoVax has moved into the final pre-clinical-deployment phase of its EMA-aligned clinical program. In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex(R), would be sufficient to evaluate GEO-MVA’s efficacy. This provides a clear, accelerated regulatory path to licensure. This milestone coincides with increasing Mpox activity globally – including expanding Clade I outbreaks in Africa and emerging cases in the United States – exposing vulnerabilities associated with global dependence on a sole foreign MVA vaccine supplier. GEO-MVA is designed to expand supply, diversify sources, and strengthen biodefense infrastructure.

Volato Group, Inc. (NYSE American: SOAR, $.6059, +4.47%) and M2i Global, Inc. (MTWO, $.055, +3.38%), a company specializing in the development and execution of a complete global value supply chain for critical minerals, recently announced key developments in its pending all-stock merger with M2i Global, Inc.. Volato has filed the Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”), following the SEC’s completion of its review of the initial confidential submission. With the reopening of federal agencies following the recent government shutdown, both companies now anticipate closing the merger in the first quarter of 2026, pending completion of SEC review and shareholder approval.

On Jan. 9, M2i Global and Volato Group announced that they have entered into a strategic collaboration agreement with Australian company Titanium X to advance critical mineral development in the US. This partnership represents a significant move towards enhancing domestic refining capacity and strengthening the critical materials supply chain that underpins US industry and national security. Titanium X and M2i Global will work together on the financing, development and commercialisation of the former’s critical mineral assets. M2i Global will apply its global experience in delivering mineral projects to support these initiatives. The companies are also in talks to conclude an exclusive titanium concentrate supply agreement.

On Jan. 7, M2i Global, Inc. along with Volato Group, Inc. (“Volato”) (NYSE American: SOAR), a technology-driven company, announced a strategic collaboration agreement with Titanium X, marking a major step forward in advancing domestic refining capabilities and securing the critical materials supply chain essential to U.S. industry and national security.

Volato Group, Inc. today (Dec. 29) announced the appointment of Alan D. Gaines to its Board of Directors, effective immediately. Mr. Gaines will also serve as Chairman of the Audit Committee.

On Dec. 23, Volato Group, Inc. announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against its strategic and balance sheet objectives. For the fourth quarter of 2025, Volato expects to report revenue between $27 million and $28 million. For the full year 2025, the Company anticipates total revenue between $78 million and $79 million, with net income of $6 million to $8 million. These results reflect a year of meaningful progression aligning operational performance with Volato’s long-term growth initiatives and advancing its pending merger with M2i Global, Inc. (OTC: MTWO). During 2025, Volato also made substantial progress strengthening its balance sheet. As of September 30, 2025, the Company reduced total liabilities to $9.5 million, satisfying the debt reduction condition required under its pending merger agreement with M2i Global, Inc. (OTC: MTWO). Volato expects continued improvement in its capital structure as it advances toward a targeted first-quarter 2026 closing of the transaction. “Our 2025 results reflect a year of transformation and disciplined balance sheet execution,” said Mark Heinen, Chief Financial Officer of Volato. “We made significant progress reducing liabilities while sharpening our focus on scalable, technology-driven businesses that are designed to complement and strengthen the M2i Global platform over the long term.”

Volato Group, Inc. announced recently that it has set a preliminary date of February 26, 2026 and preliminary record date of January 17, 2026 for a special meeting of shareholders to vote on the proposed merger with M2i Global, Inc. (MTWO) and related matters. The preliminary meeting date and record date remain subject to applicable regulatory and exchange requirements, including the effectiveness of Volato’s Registration Statement on Form S-4 (File No. 333-292132) (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (“SEC”) and the mailing of definitive proxy materials to shareholders. The proposed merger creates a combined company built for scale. M2i Global brings a platform focused on critical minerals and national supply chain resilience, while Volato contributes proven aviation technology, software capability, and an established track record of operational execution. Together, the companies aim to participate in a U.S. critical minerals market estimated at more than $320 billion annually.

Critical Metals Corp. (CRML, $17.93, +32.58%), a leading critical minerals mining company, today announced that the first assay results from the 2025 drilling program have been received from the Fjord Deposit and Upper Fjord areas at the Tanbreez Rare Earths Project in Greenland.

Serina Therapeutics (NYSE American: SER, $2.67, +8.54%), Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies. On Dec. 11, Serina announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development.

On Dec. 10, Serina announced that it has submitted a complete response to the U.S. Food and Drug Administration’s (“FDA”) clinical hold letter for SER-252, the Company’s lead program for advanced Parkinson’s disease. As previously disclosed, the FDA placed the Company’s Investigational New Drug (“IND”) application for SER-252 on clinical hold pending additional information related to a commonly used formulation excipient. On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b. The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device (Enable Injections) or the broader 505(b)(2) NDA development pathway previously discussed with the Agency.

The InterGroup Corporation (NASDAQ: INTG, $31.67, +0.00%) announced (Jan. 6) that on December 29, 2025, it completed the sale of a non-core 12-unit apartment complex in Los Angeles County for a gross sales price of approximately $4,850,000. InterGroup expects to report a GAAP net gain on sale of approximately $3,509,000, which will be reflected in the Company’s Form 10‑Q for the quarter ended December 31, 2025. The transaction is expected to result in federal and state income tax liability, the amount of which will be determined based on the Company’s final tax position and applicable tax rules.

DoubleVerify Holdings Inc. (DV) closed at $10.63. DoubleVerify, which built its franchise on media verification and ad performance analytics, is now the first badged TikTok Marketing Partner focused specifically on attention measurement, tapping impression-level signals from the platform. Brands gain a granular view of how exposure and user interaction come together across TikTok formats, ad sets, creatives, and objectives, effectively treating every swipe as a tiny A/B test.

flyExclusive, Inc. (NYSE American: FLYX, $3.69), one of the nation’s largest private jet operators and a certified Part 145 Repair Station, today announced it has signed an authorized dealership agreement with Starlink, becoming a certified dealer and installer for Starlink’s high-speed, low-latency aviation connectivity system.

The Sources

1. https://home.treasury.gov/resource-center/data-chart-center/interest-rates/TextView?type=daily_treasury_yield_curve&field_tdr_date_value=2026
2. https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-14-2026
3. https://www.marketwatch.com/livecoverage/stock-market-today-dow-sp500-nasdaq-dip-gold-silver-records-supreme-court-tariff-goldman-earnings/card/small-cap-companies-get-chance-to-shine-as-russell-2000-outperforms-in-2026-wIC8T8D0oAudzC0xlAfV
4. https://www.barrons.com/livecoverage/stock-market-news-today-011426/card/nasdaq-drops-1-small-stocks-take-lead-from-big-tech–4SP73wyThk4PhB7mspng?modCode=hp_LEDE_C_LC_1
5. https://www.nasdaq.com/articles/producer-price-index-increased-less-expected
6. https://www.bloomberg.com/news/newsletters/2026-01-13/tariff-pass-through-limited-so-far-us-data-show-evening-briefing-americas
7. https://finance.yahoo.com/news/us-tariff-revenue-dropped-by-almost-3-billion-from-november-to-december-195304841.html
8. https://finimize.com/content/shutdown-delays-rewired-the-us-data-calendar
9. https://tradingeconomics.com/united-states/government-bond-yield
10. https://www.wisdomtree.com/investments/blog/2026/01/14/putting-a-steeper-yield-curve-to-the-test
11. https://ycharts.com/indicators/20_year_treasury_rate
12. https://www.clevelandfed.org/indicators-and-data/yield-curve-and-predicted-gdp-growth
13. https://www.federalreserve.gov/newsevents/2026-january.htm
14. https://www.federalreserve.gov/monetarypolicy/fomccalendars.htm
15. http://business.times-online.com/times-online/article/marketminute-2026-1-14-the-great-yield-curve-reset-bank-of-america-and-wells-fargo-lead-the-financial-sector-into-a-pivotal-2026
16. https://finviz.com/news/275700/stock-market-today-dow-jones-nasdaq-100-futures-tumble-ahead-of-supreme-court-ruling-on-trumps-tariffs-wells-fargo-bp-weride-in-focus
17. https://www.economies.com/crypto/analysis/forecast-update-for-bitcoin–14-01-2026-124084
18. https://www.home.saxo/content/articles/macro/market-quick-take—14-january-2026-14012026
19. https://forex24.pro/bitcoin-forecast/bitcoin-forecast-and-btc-usd-analysis-for-january-14-2026/
20. https://www.bloomberg.com/news/articles/2026-01-13/stock-market-today-dow-s-p-live-updates
21. https://www.zacks.com/stock/news/2817312/heres-why-eli-lilly-lly-is-a-strong-momentum-stock
22. https://www.nasdaq.com/articles/it-time-dump-your-shares-eli-lilly-0
23. https://247wallst.com/forecasts/2026/01/12/eli-lilly-lly-stock-price-prediction-and-forecast-2025-2030/
24. https://finviz.com/news/276599/why-eli-lilly-stock-gained-392-in-2025
25. https://finance.yahoo.com/news/revenue-keeps-growing-taiwan-semi-212905504.html
26. https://finance.yahoo.com/news/tsmc-tsm-gets-price-target-210710185.html
27. https://www.benzinga.com/markets/tech/26/01/49898647/forget-the-beat-taiwan-semiconductor-2026-outlook-is-the-real-market-mover
28. https://www.cnbc.com/2026/01/12/mondays-biggest-analyst-calls-on-wall-street.html
29. https://finance.yahoo.com/news/high-growth-us-tech-stocks-113828032.html
30. https://www.alphasophia.com/blog-post/jpmorgan-healthcare-conference-2026-trends-tensions-takeaways-from-the-super-bowl-of-healthcare
31. https://www.statnews.com/2026/01/14/jpm-2026-day-3-top-stories-sanofi-bms-pfizer-biontech/
32. https://www.morningstar.com/news/marketwatch/20260114144/four-reasons-to-buy-this-overlooked-group-of-stocks-early-in-2026
33. https://www.fiercehealthcare.com/finance/jpm26-day-3-sun-rises-conferences-final-full-day
34. https://www.marketscreener.com/news/recordati-14-january-2026-j-p-morgan-healthcare-conference-presentation-ce7e58d9d88cf32c
35. https://fred.stlouisfed.org/series/DGS10
36. https://www.ustreasuryyieldcurve.com
37. https://bankingjournal.aba.com/2024/08/fomc-releases-tentative-meeting-schedule-for-2025-2026/
38. https://finance.yahoo.com/news/prediction-underperforming-nasdaq-8-last-172000462.html
39. https://verifiedinvesting.com/blogs/live-show-recap/my-trading-game-plan-revealed-01-14-2026-s-p-wedge-break-looms-as-rates-rise-and-ai-data-center-power-risk
40. https://finviz.com/news/276000/is-it-time-to-dump-your-shares-of-eli-lilly
41. https://finance.yahoo.com/news/heres-why-eli-lilly-lly-145004555.html
42. https://finance.yahoo.com/quote/LLY/
43. https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-forecasts-weak-sales-weight-loss-drug-fourth-quarter-2025-01-14/
44. https://finance.yahoo.com/video/eli-lilly-stock-soars-highs-163152645.html
45. https://www.marketbeat.com/instant-alerts/rep-gilbert-ray-cisneros-jr-sells-off-shares-of-taiwan-semiconductor-manufacturing-company-ltd-nysetsm-2026-01-14/